Use of composition containing ACEI in preparing medicine for treating hyperhomocysteinemia injury and related diseases thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of cysteinemia and composition, which is applied in the field of application of a composition containing ACEI in the preparation of medicines for treating hyperhomocysteinemia damage and related diseases, and can solve the problem of insufficient Hcy, Issues such as no folic acid composite end point and insufficient effect were observed
Inactive Publication Date: 2009-04-01
BEIJING HUAANFO BIOMEDICAL RES CENT +1
View PDF1 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0008] At present, a number of clinical studies on supplementing B vitamins such as folic acid, VB12, and VB6 to reduce Hcy and observe cardiovascular and cerebrovascular end points have been completed. However, contrary to expectations, almost all large-scale clinical studies such as VISP, NORVIT, HOPE2, and WACFAS have not observed As far as the efficacy of folic acid on the composite endpoint of cardiovascular and cerebrovascular events, and even all secondary endpoints, only the HOPE2 study observed possible beneficial results of folic acid on the secondary endpoint, but the author believes that it may not be related to the effect of folic acid
Such a result may be due to two factors: the degree of Hcy reduction is insufficient, and some studies believe that a greater degree of Hcy reduction can obtain better stroke outcomes [Wang X, Qin X, Demirtas H, et al.Efficacy of folic Acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876-1882.]; For the body damage caused by high Hcy, the effect of folic acid alone is not sufficient
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0059] 5% povidone K-30 (solvent is absolute ethanol) appropriate amount
[0060] Magnesium Stearate Appropriate amount
[0061] Preparation Process:
[0062] (1) Take the prescribed amount of enalapril maleate and folic acid and pass through a 100-mesh sieve and mix them uniformly by the method of equal increments for subsequent use;
[0063] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;
[0064] (3) Mix the starch, microcrystalline cellulose, and sodium carboxymethyl starch according to the prescription amount and then mix evenly with the mixed raw material drug in equal increments;
[0065] (4) Add appropriate amount of binder to make soft ma...
[0084] 5% povidone K-30 (solvent is absolute ethanol) appropriate amount
[0085] Magnesium Stearate Appropriate amount
[0086] The preparation process is the same as in Example 1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a use of a pharmaceutical composition containing an angiotensin converting enzyme inhibitor and a vitamin in vitamin B family in the preparation of drugs for treating body injuries and the related diseases caused by hyperhomocysteinemia (brain stroke, ischemic heart disease, deep vein thrombosis, and the like), in particular to the drugs for treating the brain stroke. The combined use of the angiotensin converting enzyme inhibitor and the vitamin in the vitamin B family can further inhibit the proliferation of VSMC, improve the symptoms of cerebral ischemia and be better than the single use of the drug, thereby showing that the combined use of the angiotensin converting enzyme inhibitor and the vitamin in the vitamin B can be acted on the different routes and the links for delaying / treating the body injuries and the related diseases caused by Hcy and further having the overlapping effect or the synergy. At present, the single use of folic acid does not have ideal effect in the clinical treatment of high Hcy, the compound drug can be a better choice and can provide a more effective treatment proposal for treating the hyperhomocysteinemia. The use belongs to the field of pharmacy.
Description
technical field [0001] The invention relates to a pharmaceutical composition containing angiotensin-converting enzyme inhibitor (ACEI) and B vitamins used in the preparation and treatment of body damage caused by hyperhomocysteinemia and related diseases (stroke, ischemic heart disease) , deep vein thrombosis, etc.), especially in the use of stroke drugs. belongs to the field of pharmacy. Background technique [0002] Cardiovascular disease (CVD) is not only the main cause of death in developed countries, but also has become one of the main causes of death in developing countries such as China. As early as 1969, it was hypothesized that homocysteine (Hcy, a sulfur-containing amino acid) might be a risk factor for cardiovascular disease. Since then, a large number of studies have accumulated objective evidence that plasma homocysteine Cystine levels are independent of traditional risk factors such as hypertension and hyperlipidemia, and are associated with the risk of car...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more